Sign In
to Vote &
Create Storyboards.
 
A new study supports launch of Phase I clinical trial to test a designer DNA agent -- an antisense oligonucleotide that targets a gene called IRF4 -- in patients with multiple myeloma.
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard